FDA releases CAIV-T documents

FDA will ask the Vaccines and Related Biological Products Advisory Committee on Wednesday whether the benefit/risk profile of CAIV-T

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE